SCHEMBL13100992

SCHEMBL13100992

CC(C)(C)OC(=O)N1CCN(c2ccc(Br)cn2)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.51
PPARG P37231 1/20 0.48
PPARD Q03181 1/20 0.48
PPARA Q07869 1/20 0.48
RET P07949 6/20 0.47
PANK3 Q9H999 1/20 0.46
GPR119 Q8TDV5 4/20 0.46
CKS1B P61024 2/20 0.45
SKP1 P63208 2/20 0.45
SKP2 Q13309 2/20 0.45
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
MAP4K4 O95819 1/20 0.43
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ADK P55263 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13100995 0.90 AKR1C3 (0.45) AKR1C3PPARGPPARDPPARARET
SCHEMBL30480343 0.90 AKR1C3 (0.57) AKR1C3PPARGPPARDPPARARET
SCHEMBL594352 0.90 AKR1C3 (0.57) AKR1C3PPARGPPARDPPARARET
SCHEMBL29712339 0.88 AKR1C3 (0.56) AKR1C3PPARGPPARDPPARARET
SCHEMBL15827745 0.85 PPARG (0.48) PPARGPPARARETPANK3GPR119
SCHEMBL594028 0.85 CKS1B (0.59) AKR1C3RETPANK3GPR119CKS1B
SCHEMBL10151466 0.84 MAP4K4 (0.48) RETGPR119CKS1BSKP1SKP2
SCHEMBL13100993 0.83 AKR1C3 (0.46) AKR1C3PPARGPPARDPPARARET
SCHEMBL1780700 0.82 RET (0.51) AKR1C3RETGPR119CKS1BSKP1
SCHEMBL29522264 0.82 AKR1C3 (0.44) AKR1C3PPARGPPARDPPARARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. 2010-10-07 US disclosed
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. 2010-10-07 US disclosed
EP-2233484-A2 Oxazolidinone derivatives having a 7-membered heterocyclic ring Research Foundation Itsuu Laboratory (JP) 2010-09-29 EP disclosed
EP-2208729-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation Itsuu Laboratory (JP) 2010-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING NR0B2, NR0B1, NR2C2 AKR1C3 854/4885PPARG 1500/4885PPARD 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.